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Abstract: Cerebral palsy (CP) is the main cause of physical disability in childhood and is an 
important health issue that has a strong socioeconomic impact. There is no effective treatment 
for CP and therapeutic approaches report only partial benefits for affected people. In this study 
we assessed the effects of growth hormone (GH) treatment combined with psychomotor and 
cognitive stimulation in the neurodevelopment of children with CP and GH deficiency (GHD). 
The study was carried out in 11 patients (7 boys and 4 girls; 4.12 ± 1.31 years) with GHD and 
CP who were treated with recombinant GH (rGH) and psychomotor and cognitive stimulation 
during 2 months. Battelle Developmental Inventory Screening Test (BDIST) was performed 
2 months before commencing GH treatment, just before commencing GH administration, and 
after 2 months of combined treatment involving GH and cognitive stimulation. Psychomotor 
and cognitive status did not change during the period in which only cognitive stimulation was 
performed; however, significant improvements in personal and social skills, adaptive behavior, 
gross motor skills and total psychomotor abilities, receptive and total communication, cogni–
tive skills and in the total score of the test (P , 0.01), and in fine motor skills and expressive 
communication (P , 0.02) were observed after the combined treatment period. Therefore, GH 
replacement together with psychomotor and cognitive stimulation seem to be useful for the 
appropriate neurodevelopment of children with GHD and CP.
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Introduction
Nervous system plasticity and regeneration of the brain in response to both neurological 
injury and repetitive practice of different neurological stimulations have been widely 
demonstrated.1 However, achievements obtained with such stimulations usually are 
incomplete. Results are better when brain injuries occur at an early age and rehabili–
tation intervention begins promptly after the injury, since there is a greater plasticity 
when the central nervous system (CNS) is developing.2
Cerebral palsy (CP) is the most common cause of physical disability in 
  childhood3 and the estimated prevalence of CP in the general population is 2/1000.4 
CP is defined as a persistent but not progressive disorder of posture and move–
ment system, associated with functional activity limitations and sensorial, cogni–
tive, communications problems, epilepsy, and musculoskeletal system problems.4 Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Major causes for CP involve prematurity (40% to 50% of 
cases of CP), abnormal intrauterine developments due to 
fetal–maternal infections, asphyxia during delivery, brain 
trauma during labor, and delivery and complications in 
the perinatal period.5 Currently there is no cure for CP 
and therapeutical approaches show only partial benefits 
for affected individuals.1
It has been shown that most CP children have poor 
linear growth during childhood resulting in a diminished 
final adult height.6 We demonstrated that in a population 
of CP children, 70% showed impaired GH secretion.5 This 
phenomenon, could have a great importance since the GH–
plasma insulin–like growth factor (IGF–1) system plays 
an important role during CNS development, and also in 
inducing neurogenesis and increasing brain plasticity.1,7–9 
In this sense, we demonstrated that combined treatment 
involving GH replacement and adequate physical or cogni–
tive stimulation is effective in the motor rehabilitation of 
children with CP or adult patients with cognitive disorders 
after traumatic brain injury, respectively.1,10
This pilot study assessed the effects of GH replacement 
combined with psychomotor and cognitive stimulation in 
the cognitive rehabilitation of children with CP and GHD.
Method
Participants
Eleven patients with GHD and CP admitted for cognitive and 
motor rehabilitation were included in the study (7 males and   
4 females; 4.12 ± 1.31 years; range: 3 to 7 years old). Accord–
ing to the Gross Motor Function Classification System 
(GMFCS) patients’ levels ranged from I to V .11 Table 1 shows 
the main characteristics of patients studied.
ghD
The existence of GHD was detected previously in the CP 
children included in the study.5 The existence of GHD was 
established according to auxological parameters and the 
GH peak response to the insulin–induced hypoglycemia 
test. IGF–1 and plasma insulin–like growth factor binding 
protein 3 (IGFBP–3) plasma levels were measured by a solid–
phase, enzyme–labeled chemiluminiscent immunometric 
assay (Inmulite 2000, Siemens). Other pituitary hormone 
deficiencies were excluded by chemiluminiscent immu–
nometric assays (data not shown). Routine blood analyses 
(hematology and chemistry) were carried out at 2–month 
intervals (Coulter HmX, Beckman and AU400, Beckman, 
respectively).
Clinical assessments
To assess neurodevelopment in patients under study we 
used the Battelle Developmental Inventory Screening 
Test (BDIST).12 The BDIST assesses key developmental 
skills in children from 6 months to 8 years of age. The 
reliability and validity of the BDIST has been previously 
  demonstrated.13 The test comprises 96 items assessing the 
following 5 domains: personal and social skills (including 
adult interaction, expression of feelings, self–concept, peer 
interaction, copying, and social roles), adaptive behavior 
(including attention, eating, dressing, toileting, and per–
sonal responsibility), psychomotor ability, communica–
tion and cognition (including perceptual discrimination, 
memory, reasoning and academic skills, and conceptual 
development). Subdomain scores can be computed for 
psychomotor ability (fine motor skills and gross motor 
skills) and communication (expressive and receptive 
communication). Scores for each domain are expressed as 
age–equivalent scores that indicate the age (in months) at 
which a raw score is average. Total test score is obtained 
after combining the scores of all domains. 
study timing
BDIST was during 2 study periods: first, a pretreatment 
period (from 2 months before starting GH treatment 
until just before commencing it); second, a treatment 
period (from just before the beginning of GH treatment 
until 2 months after GH administration commenced) 
(Figure 1).
During the pretreatment period only psychomotor and 
cognitive stimulation was performed. During the treatment 
period all patients received GH replacement together with 
psychomotor and cognitive stimulation.
It is remarkable that before admission at our center all 
these CP children had been intensively stimulated in other 
centers, most of them since they were 1 year old.
intervention
gh treatment
The patients were treated with recombinant human GH 
(rhGH; Omnitrope, Sandoz) (subcutaneously; 30 µg/kg/day, 
5 days/week, during 2 months; after 2 months of psychomo–
tor and cognitive stimulation). Fasting blood samples were 
analyzed for routine hematology and chemistry parameters 
at 2–month intervals and plasma thyroid stimulating hormone 
(TSH), IGF–I, and IGFPB3 levels were also measured every 
2 months.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Psychomotor and cognitive stimulation
Patients received psychomotor and cognitive stimulation; 
these therapies were carried out for 45 minutes per day, 
5 days per week during 4 months.
Psychomotor and cognitive stimulation were adapted to 
the specific needs of each patient. Psychomotor stimulation 
involved tasks aimed at improving tonic–postural control, lat–
erality, breathing and relaxation, static and dynamic balance, 
motor coordination and dissociation, body image, oculomo–
tor coordination, spatial and temporal orientation, and gross 
and fine motor skills. Cognitive stimulation involved tasks 
directed at improving interaction with the environment, 
communication, attention, perception, memory, reasoning, 
and concept learning.
Data analysis
Data from each BDIST assessment were compared using a 
nonparametric test for 2 related samples (Wilcoxon signed–
rank test). The analysis was done by comparing data obtained 
before and after the 2 study periods (pretreatment and   treatment 
periods). The improvement means relative to baseline dur–
ing the pretreatment period and during the treatment period 
were compared in the same way (Wilcoxon signed–rank test) 
(**P , 0.02 and ***P , 0.01). Similar statistical analysis was 
used for evaluating plasma changes in IGF–I, IGFBP3 changes, 
total cholesterol, triglycerides, and glucose levels. Results are 
shown as the mean ± standard deviation (SD) of the mean.
Results
No undesirable side–effects were observed during or after the 
study. Plasma cholesterol and triglyceride values decreased 
significantly at the end of treatment period (Table 2); 
plasma IGF–I and IGFBP3 increased significantly (Table 2), 
but their values were not higher than the mean for the 
patient’s age (data not shown). No changes were observed 
in plasma glucose levels (Table 2) or in plasma TSH levels 
(data not shown).
Patients did not improve their psychomotor and cogni–
tive status during the pretreatment period, during which only 
psychomotor and cognitive stimulation were performed. 
However, significant improvements in all BDIST domains 
were observed when GH was administered together with 
psychomotor and cognitive stimulation; specifically, patients 
improved in personal and social skills, adaptive behavior, gross 
motor skills and total psychomotor abilities, receptive and total 
communication, cognitive skills, and in the total score of the 
Table 1 Main characteristics of the patients studied
Patient Age  
(years)
Gender PC cause Radiologic findings Motor  
impairment
GMFCS   
level
1 3 M Perinatal hypoxia PVL; plagiocephaly; corpus callosum  
hypoplasia; macrocephaly
Pi iii
2 4 F Perinatal hypoxia PVL Pi i
3 5,4 F Perinatal hypoxia PVL Pi i
4 4,8 M Postsurgical iatrogenic injury Decreased activity and volume in PO  
cortex; bilateral PO ischemia; diffuse  
cerebral edema
spastic TP V
5 3,5 M Perinatal hypoxia PVL; bilateral parietal pachygyria;  
hydrocephalus; microcephaly
Flaccid TP V
6 3,1 M Premature twins; single umbilical artery PVL; plagiocephaly; polymicrogyria spastic TP V
7 3 F Premature twins PVL; right occipital cortex and bilateral  
frontal cortex ischemic injuries
Distonic TP V
8 3 M Prematurity PVL; microcephaly Pi iii
9 3,2 M Perinatal hypoxia PVL Distonic TP V
10 5,7 F Postsurgical iatrogenic injury PVL; diffuse multicystic  
leukoencephalopathy; focal hemorrhage  
in right brain hemisphere and cerebellar  
hemispheres deep white matter;  
microcephaly
Distonic TP V
11 6,7 M Postvaccine iatrogenic injury PVL Pi i
Abbreviations: GMFCS, Gross Motor Function Classification System; F, female; M, male; PC, cerebral palsy; PI, psychomotor impairment; PO, parieto-occipital; PVl, 
periventricular leucomalacia; TP, tetraplegia.
Pre-treatment period Treatment period
2 months 2 months
123
Figure 1 study timing. 
Notes: Arrowheads: assessments by using the BDisT carried out: 2 months before 
commencing gh treatment (1), just before the beginning of the treatment (2) and 
after 2 months of gh treatment (3).Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Main plasma chemistry parameters analyzed
Patient GH peak TC TG G IGF-1 IGFBP3
Pre Post Pre Post Pre Post Pre Post Pre Post
1 4.5 205 182 75 74 82 75 34.2 89 2.33 3.1
2 6.3 181 169 102 65 89 73 28.1 256 1.7 2.9
3 2.8 194 171 41 37 70 77 53 200 3.61 4.3
4 5.3 175 168 125 104 76 85 67.2 103.3 2.5 3.8
5 1.5 225 165 186 85 72 77 25 69.5 2.2 3.6
6 6.9 193 166 125 97 75 83 31 75 1.8 3.03
7 3.4 215 171 157 110 81 79 35 125 2.1 3.1
8 4.7 186 155 114 65 92 84 69.5 89.5 3 4.2
9 7.1 177 165 145 75 74 72 25 78 1.4 1.76
10 5.2 191 164 165 108 84 96 78 162 2.9 4.06
11 4.8 187 155 128 90 74 101 67 225 1.96 3.03
Mean  
(sD)
4.77  
(1.71)
193.54  
(15.69)
166.45  
(7.51)
123.90  
(41.16)
82.72  
(22.25)
79  
(7.15)
82  
(9.27)
46.63  
(20.49)
133.84  
(66.41)
2.31  
(0.64)
3.35  
(0.73)
ss 0.003*** 0.003*** ns 0.003*** 0.003***
Note: ***P , 0.01 (Wilcoxon signed-rank test).
Abbreviations: gh peak, peak growth hormone (ng/mL) after insulin-induced hypoglycemia; TC, plasma total cholesterol (mg/dL); Tg, plasma triglycerides (mg/dL); 
g, plasma glucose (mg/dL); igF-1, plasma insulin-like growth factor (ng/mL); igFBP3, plasma insulin-like growth factor binding protein 3 (µg/mL); sD, standard deviation of 
the mean; SS, statistical significance; ns, not significant; pre, pretreatment; post, post-treatment.
scale (P , 0.01), and in fine motor skills and expressive com–
munication (P , 0.02) (Figure 2 and Table 3).
Discussion
Results from this study show that the combined treatment 
involving rhGH treatment and psychomotor and cognitive 
stimulation led to significant improvements in all BDIST 
domains during the treatment period. This indicates that the 
combined treatment clearly improved the neurodevelopment 
process of CP children by increasing their psychomotor and 
cognitive capacities and abilities. Specifically, the patients 
improved their potential to interact with their environment 
(both with adults and with their peers), affectivity, self–
concept, collaboration, and understanding of their social 
role. Moreover, patients improved their attention and abilities 
to carry out their daily living activities. In the motor area 
patients specifically improved their motor control, body coor–
dination, locomotion, performing precision activities, and, 
in general, their movement functionality. Patients increased 
their communication too (both receptive and expressive) and 
their cognitive abilities and capacities (perceptual discrimina–
tion, memory, reasoning, and concept development).
Although we did not use any control group to compare 
the results of the treatment used, we think that the pretreat–
ment period can be considered as a control, despite the 
limitations of this strategy. Moreover, patients had received 
intense stimulation before admission, without any significant 
achievements.
It has been demonstrated that early intervention in low–
birth–weight (LBW) premature infants leads to significant 
improvements in diverse cognitive parameters only in the 
heavier LBW stratum.14,15 Moreover, a systematic review 
of the literature shows that early interventions for preterm 
infants have a positive influence on cognitive outcomes in 
the short to medium term but not on motor outcomes.16 Few 
studies have described the effects of GH replacement in 
GHD CP children and most report only growth data without 
assessing any possible neurologic functional recovery.6,17,18 
GH replacement therapy in GH–deficient children has been 
reported recently to significantly improve some areas such 
as the motor–component scale and performance IQ.19 This 
agrees with our data in this study and with our previous 
report demonstrating that the combined treatment involving 
GH replacement and adequate physical therapy is effective 
in the gross motor function rehabilitation of patients with 
CP and GHD.1
The neurotrophic role of GH is now well known.7,8,20–22 
Moreover, the GH–IGF–I axis is involved in the regulation 
of brain growth, development, and metabolism.23 Recent 
data from our group demonstrate that exogenous growth 
hormone may combine with locally produced GH in increas–
ing the proliferative response of hippocampal progenitors 
to brain injury in rats.9 Thus the possibility exists that most 
of the changes we observed in our study are a consequence 
of GH inducing newborn neural cells. However, some of 
these changes seem not to be related to this putative effect 
of GH, but to an enhanced or modified metabolic turnover 
of exciters neurotransmitters, such as noradrenaline (NA) 
and dopamine (DA). The prompt appearance of some posi–
tive responses in our CP children treated with GHD, such as Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
203
gh treatment and cognitive functions in ghD CP children
0
Pers/Soc
Adap
Gross mot
Fine mot
Total mot
Rec com
Exp com
Total com
Cogn
Total
5
10
2 months before treatment
Pre-treatment
15
20
25
0
Pers/Soc
Adap
Gross mot
Fine mot
Total mot
Rec com
Exp com
Total com
Cogn
Total
5
10 2 months before treatment
Pre-treatment
15
20
25
***
***
*** ***
***
***
***
***
** **
30
A
B
Figure 2 Clinical data from the BDisT during pre-treatment and treatment periods.
Notes: A) Pre-treatment period; (B) Treatment period. horizontal axis: the different domains of the BDisT and total score of it (TOTAL) are described. Vertical axis: score 
achived. notice that different scales are used for (A) and (B). A) means and SD of the mean before (white bars) and after (grey bars) for each specific assessment. B) means 
and SD of the mean before (white bars) and after (grey bars) treatment period for each specific assessment. Statistical significance was calculated by comparing the data from 
the BDisT before and after the pre-treatment period (A) and the treatment period (B) (Wilcoxon signed-rank test). **P , 0.02 and ***P , 0.01.
  alertness and increased interaction with the environment, can–
not be explained by a putative neural stem cell proliferation 
induced by the hormone. GH neuroregulation is complex and 
a number of neurotransmitters participate in it. The pituitary 
release of the hormone is tonically inhibited by hypothalamic 
somatostatin (SS).24 In turn, NA negatively controls hypo–
thalamic SS release.25 We previously demonstrated that GH 
administration increases hypothalamic SS release, which in 
turns triggers cerebral NA and DA synthesis and release for 
negatively controlling SS.24 Thus, it is tempting to speculate Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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that in the absence of a   pituitary GH secretion, as occurs in GH 
deficiency,   hypothalamic SS secretion is weak or also deficient. 
The exogenous administration of the hormone would lead to 
increased SS tone, therefore to increased DA and NA turnover 
for maintaining the physiological feedback circuits involved in 
GH control.24 This might explain some of the early responses 
observed after GH administration in this study.
The effect of GH on plasma lipids profile is well known. 
GHD patients usually display an abnormal lipid profile char–
acterized by elevated total cholesterol, elevated low–density 
lipoprotein cholesterol, and elevated triglycerides.26 GHD 
adolescents present an abnormal fasting and postprandial 
lipid profile that, in addition to increased fibrinogen and 
homocysteine levels, suggest the accumulation of car–
diovascular risk factors early in life.27 In our study, GH 
replacement therapy significantly decreased fasting plasma 
total cholesterol and triglyceride levels, in agreement with 
that observed in other studies.26 Fasting glycemia was not 
significantly modified after 2 months of GH administration. 
As expected, plasma IGF–1 and IGFBP3 significantly 
increased too after GH treatment, indicating that GHD in 
our patients did not occur as a consequence of any mutation 
in GH receptor, but as a result of an altered hypothalamic 
control of pituitary GH release. This agrees with the fact 
that no clear anatomical abnormalities were observed in 
hypothalamic and pituitary MRI studies carried out before 
admission.
In summary, we have demonstrated that the combined 
therapy involving GH replacement and psychomotor and 
cognitive stimulation seems to be useful for the appropri–
ate neurodevelopment of children with GHD and CP. Since 
these children had received an intensive neurostimulation 
without significant improvements before being treated with 
GH, it seems to be clear that the hormone, and/or IGF–1, 
was the main factor responsible for the results obtained. 
Although this was a pilot study, and new and larger   studies 
are needed to understand more precisely the effects of GH 
treatment in patients with CP and GHD, accumulating 
evidence (this and our previous studies) shows that GH 
administration improves both motor and cognitive abili–
ties in GHD CP children. Since exogenous GH combines 
with locally produced GH for repairing brain injuries,9 it is 
feasible to assume that GH treatment may be used too in 
CP children without GHD. Because GH treatments last a 
few months, and GH doses are not higher than those used 
for treating GH deficiency, no significant risks seem to be 
associated with GH treatment in CP children in whom GH 
secretion is normal.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Figure 3 Comparison of improvements during pre-treatment and treatment periods. 
Notes: The horizontal axis shows the different domains of the BDisT and the total (TOTAL) score of the test. The vertical axis shows the percentage improvements 
observed during the pre-treatment period (white bars) and treatment period (grey bars) over baseline values for each specific assessment (mean + SD). Statistical significance 
was calculated by comparing the improvements relative to baseline from the BDisT during pre-treatment periods (Wilcoxon signed-rank test). **P , 0.02 and ***P , 0.01.
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